Sacral and Percutaneous Tibial Nerve Stimulation, Stem Cell Therapy, and Transanal Irrigation Device

Naldini, Gabriele; Sturiale, Alessandro; Menconi, Claudia; Fabiani, Bernardina; Aglietti, Rebecca; Fralleone, Lisa; Annicchiarico, Alfredo; Martellucci, Jacopo

doi:10.1007/978-3-031-08392-1_10

Cited by 2 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Washington et al 31 had two patients undergoing reimplant at 14 and 16 days, and both procedures were uncomplicated and no infection developed at follow‐up. Naldini et al 24 suggests reimplantation should be taken at least 6‐months post explantation.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of the infected sacral nerve stimulator: A scoping review

Wynn,

Kelsey,

McLeod

2024

Neurourology and Urodynamics

View full text Add to dashboard Cite

BackgroundSacral nerve stimulators (SNSs) are a widely accepted, efficacious surgical option to treat patients who have failed conservative management for overactive bladder, nonobstructive urinary retention, fecal incontinence, or pelvic pain. As with all implanted devices, there are associated risks for surgical site and implant infections. There are currently no clear published data or guidelines regarding treating such infections.AimsWe present a scoping review aiming to examine the existing literature on the treatment approaches of infected SNSs.MethodsA scoping review was conducted using Preferred Reporting Items for Systematic Review and Meta‐Analysis. The search strategy focused on “sacral modulation,” and “infection,” and “explantation,” and conservative management methods such as “antibiotics.” A search was conducted on medical databases, and a grey literature search was performed.ResultsThirty articles were included for data extraction. Articles were published between 2006 and 2022. Outcomes were reported for 7446 patients. Two hundred and seventy‐four infection events were reported, giving an overall 3.7% infection rate. Most infection events were treated with explantation, although there is some discussion on the role of conservative management using oral and intravenous antibiotics in the literature. Articles also discussed considerations for future reimplantation after explantation of SNS.ConclusionsThere are currently no treatment protocols in the literature to help guide whether a patient is suited to conservative or surgical management. There is future scope for developing treatment algorithms to guide clinicians for optimal treatment of infected sacral neuromodulation devices.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Eighteen articles did not specify the degree of infection. 6,7,[10][11][12]14,15,19,20,24,25,[27][28][29]31,32,34,35 Seven articles discuss superficial infections, 8,10,18,22,23,30,34 eight articles discuss deep infections. 2,5,8,18,21,26,33,34 One case report highlights an episode of sepsis due to SNS infection.…”

Section: Types Of Infection and Infection Ratementioning

confidence: 99%

Treatment of the infected sacral nerve stimulator: A scoping review

Wynn,

Kelsey,

McLeod

2024

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

Sacral Neuromodulation for defecation disorders after non oncologic pelvic surgery

Martellucci,

Annicchiarico,

Scheiterle

et al. 2023

Int J Colorectal Dis

Self Cite

View full text Add to dashboard Cite

Purpose Defecation disorders (DD) can sometimes affect the outcomes of pelvic or colorectal surgery. The aim of the present study is to evaluate the role of sacral neuromodulation for the treatment of constipation and other evacuation disorders after surgery. Methods A retrospective analysis in all the consecutive patients that underwent sacral nerve modulation (SNM) for DD arisen or worsened after pelvic or colorectal surgery was performed from January 2010 to December 2020. DD were defined starting from Rome IV Criteria, and according to manometric results, all patients were further divided into the two subgroups: inadequate defecatory propulsion and dyssynergic defecation. Cleveland Clinic Constipations Score (CCCS) and SF-36 have been evaluated in the time. Results Thirty-seven patients have been included in the study. Twenty-seven out of thirty-seven (73.3%) patients had experienced sufficient benefits to implant the definitive device, and 22 patients (59.4% of tested and 81.5% of permanently implanted) still had the device functioning after a mean follow-up of 6.3 years. The most represented manometric pattern was inadequate propulsive function (59% of patients). CCCS at preoperative assessment for all patients was 17.5 with a reduction to 10.4 at the first year of follow-up (p < 0.001). Conclusion SNM appears to be a feasible, safe, and well-tolerated procedure with durable benefit in the long-term treatment of defecatory dysfunction after pelvic or colorectal surgery for benign diseases.

show abstract

Sacral and Percutaneous Tibial Nerve Stimulation, Stem Cell Therapy, and Transanal Irrigation Device

Cited by 2 publications

References 41 publications

Treatment of the infected sacral nerve stimulator: A scoping review

Treatment of the infected sacral nerve stimulator: A scoping review

Sacral Neuromodulation for defecation disorders after non oncologic pelvic surgery

Contact Info

Product

Resources

About